Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 59 entries
Sorted by: Best Match Show Resources per page
Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer.

Clinical epigenetics

Bauden M, Pamart D, Ansari D, Herzog M, Eccleston M, Micallef J, Andersson B, Andersson R.
PMID: 26451166
Clin Epigenetics. 2015 Oct 07;7:106. doi: 10.1186/s13148-015-0139-4. eCollection 2015.

BACKGROUND: To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes...

Cite
Bauden M, Pamart D, Ansari D, et al. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin Epigenetics. 2015;7:106doi: 10.1186/s13148-015-0139-4.
Bauden, M., Pamart, D., Ansari, D., Herzog, M., Eccleston, M., Micallef, J., Andersson, B., & Andersson, R. (2015). Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clinical epigenetics, 7106. https://doi.org/10.1186/s13148-015-0139-4
Bauden, Monika, et al. "Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer." Clinical epigenetics vol. 7 (2015): 106. doi: https://doi.org/10.1186/s13148-015-0139-4
Bauden M, Pamart D, Ansari D, Herzog M, Eccleston M, Micallef J, Andersson B, Andersson R. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin Epigenetics. 2015 Oct 07;7:106. doi: 10.1186/s13148-015-0139-4. eCollection 2015. PMID: 26451166; PMCID: PMC4597435.
Copy Download .nbib Format: NLM
Effect of desipramine on patients with breathing disorders in RETT syndrome.

Annals of clinical and translational neurology

Mancini J, Dubus JC, Jouve E, Roux JC, Franco P, Lagrue E, Castelnau P, Cances C, Chaix Y, Rougeot-Jung C, Cornu C, Desportes V, Vallée L, Bahi-Buisson N, Truillet R, Attolini L, Villard L, Blin O, Micallef J.
PMID: 29468173
Ann Clin Transl Neurol. 2017 Dec 27;5(2):118-127. doi: 10.1002/acn3.468. eCollection 2018 Feb.

OBJECTIVE: Rett Syndrome (RTT) is a severe neurodevelopmental condition with breathing disorders, affecting around one in 10,000 female births. Desipramine, a noradrenaline reuptake inhibitor, reduced the number of apneas in Mecp2-deficient mice, a model of RTT. We planned a...

Cite
Mancini J, Dubus JC, Jouve E, et al. Effect of desipramine on patients with breathing disorders in RETT syndrome. Ann Clin Transl Neurol. 2017;5(2):118-127doi: 10.1002/acn3.468.
Mancini, J., Dubus, J. C., Jouve, E., Roux, J. C., Franco, P., Lagrue, E., Castelnau, P., Cances, C., Chaix, Y., Rougeot-Jung, C., Cornu, C., Desportes, V., Vallée, L., Bahi-Buisson, N., Truillet, R., Attolini, L., Villard, L., Blin, O., & Micallef, J. (2018). Effect of desipramine on patients with breathing disorders in RETT syndrome. Annals of clinical and translational neurology, 5(2), 118-127. https://doi.org/10.1002/acn3.468
Mancini, Josette, et al. "Effect of desipramine on patients with breathing disorders in RETT syndrome." Annals of clinical and translational neurology vol. 5,2 (2018): 118-127. doi: https://doi.org/10.1002/acn3.468
Mancini J, Dubus JC, Jouve E, Roux JC, Franco P, Lagrue E, Castelnau P, Cances C, Chaix Y, Rougeot-Jung C, Cornu C, Desportes V, Vallée L, Bahi-Buisson N, Truillet R, Attolini L, Villard L, Blin O, Micallef J. Effect of desipramine on patients with breathing disorders in RETT syndrome. Ann Clin Transl Neurol. 2017 Dec 27;5(2):118-127. doi: 10.1002/acn3.468. eCollection 2018 Feb. PMID: 29468173; PMCID: PMC5817841.
Copy Download .nbib Format: NLM
Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.

Orphanet journal of rare diseases

Attarian S, Vallat JM, Magy L, Funalot B, Gonnaud PM, Lacour A, Péréon Y, Dubourg O, Pouget J, Micallef J, Franques J, Lefebvre MN, Ghorab K, Al-Moussawi M, Tiffreau V, Preudhomme M, Magot A, Leclair-Visonneau L, Stojkovic T, Bossi L, Lehert P, Gilbert W, Bertrand V, Mandel J, Milet A, Hajj R, Boudiaf L, Scart-Grès C, Nabirotchkin S, Guedj M, Chumakov I, Cohen D.
PMID: 27387831
Orphanet J Rare Dis. 2016 Jul 07;11(1):92. doi: 10.1186/s13023-016-0463-6.

No abstract available.

Cite
Attarian S, Vallat JM, Magy L, et al. Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis. 2016;11(1):92doi: 10.1186/s13023-016-0463-6.
Attarian, S., Vallat, J. M., Magy, L., Funalot, B., Gonnaud, P. M., Lacour, A., Péréon, Y., Dubourg, O., Pouget, J., Micallef, J., Franques, J., Lefebvre, M. N., Ghorab, K., Al-Moussawi, M., Tiffreau, V., Preudhomme, M., Magot, A., Leclair-Visonneau, L., Stojkovic, T., Bossi, L., Lehert, P., Gilbert, W., Bertrand, V., Mandel, J., Milet, A., Hajj, R., Boudiaf, L., Scart-Grès, C., Nabirotchkin, S., Guedj, M., Chumakov, I., & Cohen, D. (2016). Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet journal of rare diseases, 11(1), 92. https://doi.org/10.1186/s13023-016-0463-6
Attarian, Shahram, et al. "Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A." Orphanet journal of rare diseases vol. 11,1 (2016): 92. doi: https://doi.org/10.1186/s13023-016-0463-6
Attarian S, Vallat JM, Magy L, Funalot B, Gonnaud PM, Lacour A, Péréon Y, Dubourg O, Pouget J, Micallef J, Franques J, Lefebvre MN, Ghorab K, Al-Moussawi M, Tiffreau V, Preudhomme M, Magot A, Leclair-Visonneau L, Stojkovic T, Bossi L, Lehert P, Gilbert W, Bertrand V, Mandel J, Milet A, Hajj R, Boudiaf L, Scart-Grès C, Nabirotchkin S, Guedj M, Chumakov I, Cohen D. Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis. 2016 Jul 07;11(1):92. doi: 10.1186/s13023-016-0463-6. PMID: 27387831; PMCID: PMC4937550.
Copy Download .nbib Format: NLM
Warning on increased serious health complications related to non-medical use of nitrous oxide.

Therapie

, Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, Gillet P.
PMID: 32063400
Therapie. 2021 Sep-Oct;76(5):478-479. doi: 10.1016/j.therap.2020.01.002. Epub 2020 Jan 17.

No abstract available.

Cite
, Micallef J, Mallaret M, et al. Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapie. 2020;76(5):478-479doi: 10.1016/j.therap.2020.01.002.
, Micallef, J., Mallaret, M., Lapeyre-Mestre, M., Daveluy, A., Victorri-Vigneau, C., Peyrière, H., Debruyne, D., Deheul, S., Bordet, R., Chevallier, C., Perault-Pochat, M. C., Le Boisselier, R., Libert, F., Chaouachi, L., & Gillet, P. (2021). Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapie, 76(5), 478-479. https://doi.org/10.1016/j.therap.2020.01.002
, et al. "Warning on increased serious health complications related to non-medical use of nitrous oxide." Therapie vol. 76,5 (2021): 478-479. doi: https://doi.org/10.1016/j.therap.2020.01.002
, Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, Gillet P. Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapie. 2021 Sep-Oct;76(5):478-479. doi: 10.1016/j.therap.2020.01.002. Epub 2020 Jan 17. PMID: 32063400.
Copy Download .nbib Format: NLM
Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level.

Clinical pharmacology and therapeutics

Chouchana L, Blet A, Al-Khalaf M, Kafil TS, Nair G, Robblee J, Drici MD, Valnet-Rabier MB, Micallef J, Salvo F, Treluyer JM, Liu PP.
PMID: 34860360
Clin Pharmacol Ther. 2021 Dec 03; doi: 10.1002/cpt.2499. Epub 2021 Dec 03.

Myocarditis and pericarditis may constitute adverse reactions of mRNA COVID-19 vaccines. This study aimed to document these reactions and to assess the association with patient sex and age. This is as an observational retrospective study using a case-non-case design...

Cite
Chouchana L, Blet A, Al-Khalaf M, et al. Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level. Clin Pharmacol Ther. 2021;doi: 10.1002/cpt.2499.
Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., Drici, M. D., Valnet-Rabier, M. B., Micallef, J., Salvo, F., Treluyer, J. M., & Liu, P. P. (2021). Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level. Clinical pharmacology and therapeutics, . https://doi.org/10.1002/cpt.2499
Chouchana, Laurent, et al. "Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level." Clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.1002/cpt.2499
Chouchana L, Blet A, Al-Khalaf M, Kafil TS, Nair G, Robblee J, Drici MD, Valnet-Rabier MB, Micallef J, Salvo F, Treluyer JM, Liu PP. Features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level. Clin Pharmacol Ther. 2021 Dec 03; doi: 10.1002/cpt.2499. Epub 2021 Dec 03. PMID: 34860360.
Copy Download .nbib Format: NLM
Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program.

Fundamental & clinical pharmacology

Dumonceau RG, Soeiro T, Lacroix C, Giocanti A, Frauger É, Mezaache S, Micallef J.
PMID: 34837277
Fundam Clin Pharmacol. 2021 Nov 27; doi: 10.1111/fcp.12738. Epub 2021 Nov 27.

Accumulating evidence shows that some antidepressants are abused for their psychostimulant effects, but the extent of antidepressants abuse is unknown in subjects with opioid use disorders (OUD). The objective of this work is to assess the prevalence of antidepressant...

Cite
Dumonceau RG, Soeiro T, Lacroix C, et al. Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program. Fundam Clin Pharmacol. 2021;doi: 10.1111/fcp.12738.
Dumonceau, R. G., Soeiro, T., Lacroix, C., Giocanti, A., Frauger, �. �., Mezaache, S., & Micallef, J. (2021). Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program. Fundamental & clinical pharmacology, . https://doi.org/10.1111/fcp.12738
Dumonceau, Robinson Gravier, et al. "Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program." Fundamental & clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/fcp.12738
Dumonceau RG, Soeiro T, Lacroix C, Giocanti A, Frauger É, Mezaache S, Micallef J. Antidepressants abuse in subjects with opioid use disorders: A 10-year study in the French OPPIDUM program. Fundam Clin Pharmacol. 2021 Nov 27; doi: 10.1111/fcp.12738. Epub 2021 Nov 27. PMID: 34837277.
Copy Download .nbib Format: NLM
Design of an Intramuscular Injection Simulator: Accommodating Cultural Differences.

Cureus

Micallef J, Lin AC, Arutiunian A, Dubrowski A.
PMID: 34820235
Cureus. 2021 Oct 22;13(10):e18980. doi: 10.7759/cureus.18980. eCollection 2021 Oct.

We had developed an inexpensive intramuscular (IM) injection simulator and gathered feedback from Canadian hospital-based practicing nurses about the design features of the simulator. While the feedback critiqued the density of the simulator as being too stiff and suggested...

Cite
Micallef J, Lin AC, Arutiunian A, et al. Design of an Intramuscular Injection Simulator: Accommodating Cultural Differences. Cureus. 2021;13(10):e18980doi: 10.7759/cureus.18980.
Micallef, J., Lin, A. C., Arutiunian, A., & Dubrowski, A. (2021). Design of an Intramuscular Injection Simulator: Accommodating Cultural Differences. Cureus, 13(10), e18980. https://doi.org/10.7759/cureus.18980
Micallef, Julia, et al. "Design of an Intramuscular Injection Simulator: Accommodating Cultural Differences." Cureus vol. 13,10 (2021): e18980. doi: https://doi.org/10.7759/cureus.18980
Micallef J, Lin AC, Arutiunian A, Dubrowski A. Design of an Intramuscular Injection Simulator: Accommodating Cultural Differences. Cureus. 2021 Oct 22;13(10):e18980. doi: 10.7759/cureus.18980. eCollection 2021 Oct. PMID: 34820235; PMCID: PMC8607311.
Copy Download .nbib Format: NLM
A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).

Drug safety

Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A.
PMID: 34714529
Drug Saf. 2021 Oct 29; doi: 10.1007/s40264-021-01124-5. Epub 2021 Oct 29.

INTRODUCTION: Analgesics are among the most widely used drugs worldwide. This study describes the population treated with narcotic analgesics, their therapeutic indications and how the data have evolved over a decade.METHODS: A cross-sectional, national, multicentre survey study was conducted...

Cite
Perri-Plandé J, Miremont-Salamé G, Micallef J, et al. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Saf. 2021;doi: 10.1007/s40264-021-01124-5.
Perri-Plandé, J., Miremont-Salamé, G., Micallef, J., Herman, C., Baumevieille, M., Abriat, F., Lapeyre-Mestre, M., Haramburu, F., Daveluy, A. (2021). A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug safety, . https://doi.org/10.1007/s40264-021-01124-5
Perri-Plandé, Joelle, et al. "A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019)." Drug safety vol. (2021). doi: https://doi.org/10.1007/s40264-021-01124-5
Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Saf. 2021 Oct 29; doi: 10.1007/s40264-021-01124-5. Epub 2021 Oct 29. PMID: 34714529.
Copy Download .nbib Format: NLM
Adverse drug reaction monitoring: Doing it the French way - Act II.

Therapie

Soeiro T, Lacroix C, Micallef J.
PMID: 33190850
Therapie. 2021 Sep-Oct;76(5):385-387. doi: 10.1016/j.therap.2020.11.002. Epub 2020 Nov 06.

No abstract available.

Cite
Soeiro T, Lacroix C, Micallef J. Adverse drug reaction monitoring: Doing it the French way - Act II. Therapie. 2020;76(5):385-387doi: 10.1016/j.therap.2020.11.002.
Soeiro, T., Lacroix, C., & Micallef, J. (2021). Adverse drug reaction monitoring: Doing it the French way - Act II. Therapie, 76(5), 385-387. https://doi.org/10.1016/j.therap.2020.11.002
Soeiro, Thomas, et al. "Adverse drug reaction monitoring: Doing it the French way - Act II." Therapie vol. 76,5 (2021): 385-387. doi: https://doi.org/10.1016/j.therap.2020.11.002
Soeiro T, Lacroix C, Micallef J. Adverse drug reaction monitoring: Doing it the French way - Act II. Therapie. 2021 Sep-Oct;76(5):385-387. doi: 10.1016/j.therap.2020.11.002. Epub 2020 Nov 06. PMID: 33190850.
Copy Download .nbib Format: NLM
Serious Neurological Adverse Events of Ceftriaxone.

Antibiotics (Basel, Switzerland)

Lacroix C, Bera-Jonville AP, Montastruc F, Velly L, Micallef J, Guilhaumou R.
PMID: 34066591
Antibiotics (Basel). 2021 May 06;10(5). doi: 10.3390/antibiotics10050540.

We described ceftriaxone-induced CNS adverse events through the largest case series of Adverse Drug Reactions (ADRs) reports, from 1995 to 2017, using the French Pharmacovigilance Database. In total, 152 cases of serious CNS ADRs were analyzed; 112 patients were...

Cite
Lacroix C, Bera-Jonville AP, Montastruc F, et al. Serious Neurological Adverse Events of Ceftriaxone. Antibiotics (Basel). 2021;10(5)doi: 10.3390/antibiotics10050540.
Lacroix, C., Bera-Jonville, A. P., Montastruc, F., Velly, L., Micallef, J., & Guilhaumou, R. (2021). Serious Neurological Adverse Events of Ceftriaxone. Antibiotics (Basel, Switzerland), 10(5), . https://doi.org/10.3390/antibiotics10050540
Lacroix, Clémence, et al. "Serious Neurological Adverse Events of Ceftriaxone." Antibiotics (Basel, Switzerland) vol. 10,5 (2021). doi: https://doi.org/10.3390/antibiotics10050540
Lacroix C, Bera-Jonville AP, Montastruc F, Velly L, Micallef J, Guilhaumou R. Serious Neurological Adverse Events of Ceftriaxone. Antibiotics (Basel). 2021 May 06;10(5). doi: 10.3390/antibiotics10050540. PMID: 34066591; PMCID: PMC8148437.
Copy Download .nbib Format: NLM
A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).

Drug safety

Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A.
PMID: 34714529
Drug Saf. 2022 Jan;45(1):37-44. doi: 10.1007/s40264-021-01124-5. Epub 2021 Oct 29.

INTRODUCTION: Analgesics are among the most widely used drugs worldwide. This study describes the population treated with narcotic analgesics, their therapeutic indications and how the data have evolved over a decade.METHODS: A cross-sectional, national, multicentre survey study was conducted...

Cite
Perri-Plandé J, Miremont-Salamé G, Micallef J, et al. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Saf. 2021;45(1):37-44doi: 10.1007/s40264-021-01124-5.
Perri-Plandé, J., Miremont-Salamé, G., Micallef, J., Herman, C., Baumevieille, M., Abriat, F., Lapeyre-Mestre, M., Haramburu, F., Daveluy, A. (2022). A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug safety, 45(1), 37-44. https://doi.org/10.1007/s40264-021-01124-5
Perri-Plandé, Joelle, et al. "A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019)." Drug safety vol. 45,1 (2022): 37-44. doi: https://doi.org/10.1007/s40264-021-01124-5
Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019). Drug Saf. 2022 Jan;45(1):37-44. doi: 10.1007/s40264-021-01124-5. Epub 2021 Oct 29. PMID: 34714529.
Copy Download .nbib Format: NLM
[Not Available].

Therapie

Dhainaut JF, Bassompierre F, Misse C, Diebolt V, Pouletty-Lefèbvre B, Baker A, Borel T, Braunstein D, Demotes J, François B, Huet S, Micallef J, Molon A, Rascol O, Ravoire S, Schwartz B, Donne de N, Fusaï G, Pouletty P, Vicaut E.
PMID: 27393399
Therapie. 2015 Jan-Feb;70(1):95-102. doi: 10.2515/therapie/2014232.

No abstract available.

Cite
Dhainaut JF, Bassompierre F, Misse C, et al. Quelle stratégie française dans le cadre H2020 ? [Not Available]. Therapie. 2015;70(1):95-102doi: 10.2515/therapie/2014232.
Dhainaut, J. F., Bassompierre, F., Misse, C., Diebolt, V., Pouletty-Lefèbvre, B., Baker, A., Borel, T., Braunstein, D., Demotes, J., François, B., Huet, S., Micallef, J., Molon, A., Rascol, O., Ravoire, S., Schwartz, B., Donne, d. e. . N., Fusaï, G., Pouletty, P., & Vicaut, E. (2015). Quelle stratégie française dans le cadre H2020 ? [Not Available]. Therapie, 70(1), 95-102. https://doi.org/10.2515/therapie/2014232
Dhainaut, Jean-François, et al. "Quelle stratégie française dans le cadre H2020 ?" [Not Available]. Therapie vol. 70,1 (2015): 95-102. doi: https://doi.org/10.2515/therapie/2014232
Dhainaut JF, Bassompierre F, Misse C, Diebolt V, Pouletty-Lefèbvre B, Baker A, Borel T, Braunstein D, Demotes J, François B, Huet S, Micallef J, Molon A, Rascol O, Ravoire S, Schwartz B, Donne de N, Fusaï G, Pouletty P, Vicaut E. Quelle stratégie française dans le cadre H2020 ? [Not Available]. Therapie. 2015 Jan-Feb;70(1):95-102. doi: 10.2515/therapie/2014232. French. PMID: 27393399.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 59 entries